Research programme: anti-cancer immunotherapeutic oligonucleotides - Tekmira Pharmaceuticals

Drug Profile

Research programme: anti-cancer immunotherapeutic oligonucleotides - Tekmira Pharmaceuticals

Alternative Names: INX-0167; INX-0204; OligoVax; TKM-0167

Latest Information Update: 16 Oct 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Tekmira Pharmaceuticals Corporation
  • Class Antigens; Oligonucleotides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Bacterial infections; Viral infections

Most Recent Events

  • 31 Dec 2012 No development reported - Preclinical for Cancer in Canada (Injection)
  • 02 Jul 2009 Preclinical development in Cancer is ongoing in Canada
  • 23 Jul 2004 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top